pharmaCline Announces Merger Agreement and New Dental Division
Sioux Falls, SD, May 31, 2012 --(PR.com)-- pharmaCline, a manufacturer of innovative pharmaceutical products, announced that it has entered into a merger agreement with Concept Two Solution, LLC, a dental wound care products company located in Goodrich, Michigan. Concept Two Solution focuses on developing innovative minimally invasive dental care solutions to help providers and patients achieve optimal oral health.
“This merger furthers the pharmaCline mission of providing breakthrough products in multiple growth markets- skin and skin structure wound care and now dental wound care,” said pharmaCline CEO Steve Keough.
The founder of Concept Two Solution is Dr. Charles Cox, DMD, PhD. Along with his team members, Dr. Cox developed a broad portfolio of novel minimally invasive dental care products. Dr. Cox has been in the field of dentistry for over forty years, and has been a Professor of Dentistry at several leading academic institutions and research facilities in the United States and Japan.
“We welcome this merger with pharmaCline because of the exciting synergies between both companies. We also share a strong commitment to improving the lives of patients,” said Dr Cox.
The pharmaCline Dental Care Division will build shareholder value based on the depth and breadth of its portfolio, with a goal of launching new products each year for the foreseeable future. Initial products include a rapid acting tooth desensitizer and a novel plaque loosening material. The tooth desensitizer product utilizes an advanced formulation that reduces dental pain in less than five seconds. The plaque loosening product enables less invasive, and less painful, hygienist cleaning procedures during patient visits to dental offices. Both of these products are scheduled for immediate introduction into Canada and Japan, with release in the United States later this year.
“We are excited to join forces with Dr. Cox and his colleagues to bring patient-centric products to markets around the world,” said pharmaCline CEO Steve Keough. “These products, and others in the dental care pipeline, add to our shareholder value consistent with our mission.”
The market for dental care products, including self-care products, is growing at about 6% annually in the United States. However, the inability of patients to access dental offices is growing at a much higher rate due to economic challenges. This access to care is complicated by the demographics of longer patient lives, the desire to maintain maximum natural tooth structure, increased attention to dental aesthetics, and the difficulty of obtaining dental care under available health plans.
About pharmaCline
pharmaCline® is an innovative technology and pharmaceutical company that has developed a proprietary drug delivery technology called Site Specific Penetration Technology™. Using this technology, pharmaCline has created a game-changing product line of topical hypoallergenic antimicrobial drugs. pharmaCline’s products provide an effective solution to the antibiotic resistance crisis worldwide. Focusing on healing wounds, preventing the spread of disease, and improving lives, pharmaCline continuously seeks out breakthrough technologies and products in various markets. By remaining focused on high quality patient care in strong growth sectors, pharmaCline strives to achieve exceptional financial returns for investors.
About Concept Two Solution
Concept Two Solution is an innovative dental care company focused on novel minimally invasive solutions to improved patient outcomes. With a commitment to providing rapid acting simple solutions to patient needs, Concept Two Solution has been a premier developer of products for the ever-growing challenges of dental wound care worldwide.
Contact Information:
Lana McCoy, Executive Marketing Coordinator
Email: lmccoy@pharmacline.com
Phone: 605-271-2086
2329 N. Career Avenue, Suite 243
Sioux Falls, SD 57107
www.pharmacline.com
“This merger furthers the pharmaCline mission of providing breakthrough products in multiple growth markets- skin and skin structure wound care and now dental wound care,” said pharmaCline CEO Steve Keough.
The founder of Concept Two Solution is Dr. Charles Cox, DMD, PhD. Along with his team members, Dr. Cox developed a broad portfolio of novel minimally invasive dental care products. Dr. Cox has been in the field of dentistry for over forty years, and has been a Professor of Dentistry at several leading academic institutions and research facilities in the United States and Japan.
“We welcome this merger with pharmaCline because of the exciting synergies between both companies. We also share a strong commitment to improving the lives of patients,” said Dr Cox.
The pharmaCline Dental Care Division will build shareholder value based on the depth and breadth of its portfolio, with a goal of launching new products each year for the foreseeable future. Initial products include a rapid acting tooth desensitizer and a novel plaque loosening material. The tooth desensitizer product utilizes an advanced formulation that reduces dental pain in less than five seconds. The plaque loosening product enables less invasive, and less painful, hygienist cleaning procedures during patient visits to dental offices. Both of these products are scheduled for immediate introduction into Canada and Japan, with release in the United States later this year.
“We are excited to join forces with Dr. Cox and his colleagues to bring patient-centric products to markets around the world,” said pharmaCline CEO Steve Keough. “These products, and others in the dental care pipeline, add to our shareholder value consistent with our mission.”
The market for dental care products, including self-care products, is growing at about 6% annually in the United States. However, the inability of patients to access dental offices is growing at a much higher rate due to economic challenges. This access to care is complicated by the demographics of longer patient lives, the desire to maintain maximum natural tooth structure, increased attention to dental aesthetics, and the difficulty of obtaining dental care under available health plans.
About pharmaCline
pharmaCline® is an innovative technology and pharmaceutical company that has developed a proprietary drug delivery technology called Site Specific Penetration Technology™. Using this technology, pharmaCline has created a game-changing product line of topical hypoallergenic antimicrobial drugs. pharmaCline’s products provide an effective solution to the antibiotic resistance crisis worldwide. Focusing on healing wounds, preventing the spread of disease, and improving lives, pharmaCline continuously seeks out breakthrough technologies and products in various markets. By remaining focused on high quality patient care in strong growth sectors, pharmaCline strives to achieve exceptional financial returns for investors.
About Concept Two Solution
Concept Two Solution is an innovative dental care company focused on novel minimally invasive solutions to improved patient outcomes. With a commitment to providing rapid acting simple solutions to patient needs, Concept Two Solution has been a premier developer of products for the ever-growing challenges of dental wound care worldwide.
Contact Information:
Lana McCoy, Executive Marketing Coordinator
Email: lmccoy@pharmacline.com
Phone: 605-271-2086
2329 N. Career Avenue, Suite 243
Sioux Falls, SD 57107
www.pharmacline.com
Contact
pharmaCline
Lana McCoy
605-271-2086
www.pharmacline.com
Lana McCoy
605-271-2086
www.pharmacline.com
Contact
Categories